Results 31 to 40 of about 3,710 (152)

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension [PDF]

, 2013
BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.
Jansa P, Simonneau G, Ghofrani HA, Weimann G, Mayer E, Wang C., D'ARMINI, ANDREA MARIA, Grimminger F, Hoeper MM, Wilkins MR, Neuser D, Fritsch A, Kim NH   +12 more
core   +2 more sources

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

Pulmonary Circulation, 2017
Riociguat is a soluble guanylate cyclase stimulator used for pulmonary hypertension (PH) treatment. We evaluated right ventricular (RV) contractile function in 27 PH patients receiving riociguat.
Mitsushige Murata, Takashi Kawakami, Masaharu Kataoka, Takashi Kohno, Yuji Itabashi, Keiichi Fukuda   +5 more
doaj   +1 more source

An Unlikely Trio: Profound Anemia, Elevated Lactate, and Riociguat

, 2022
Riociguat (Adempas) is a stimulator of soluble guanylate cyclase approved to treat adult pulmonary arterial hypertension (PAH), World Health Organization (WHO) group 1 pulmonary hypertension (PH), and inoperable or persistent chronic thromboembolic ...
Farmer, Mary Jo S, MD
core   +1 more source

The contribution of the soluble guanylate cyclase stimulator riociguat to changes in functional status and hemodynamic parameters in the combined approach to treating patients with inoperable chronic thromboembolic pulmonary hypertension

Евразийский Кардиологический Журнал
Objective: to study the contribution of the soluble guanylate cyclase stimulator riociguate to the overall effect of combined treatment of patients with inoperable chronic thromboembolic pulmonary hypertension.Material and methods.
E. O. Dinevich, N. M. Danilov, I. E. Chazova   +2 more
doaj   +1 more source

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension

International Journal of Cardiology: Heart & Vasculature, 2019
Background: To improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat.
M.C.J. van Thor, L. ten Klooster, R.J. Snijder, M.C. Post, J.J. Mager   +4 more
doaj   +1 more source

Riociguat decreases hyperoxia-induced vascular remodeling.

, 2018
(A, C) Double immunofluorescence staining for vWF (green signal) and α-SMA (red signal) plus DAPI nuclear stain (blue signal). (B) Hyperoxia exposure in the presence of placebo increased muscularization of peripheral pulmonary vessels (D) Hyperoxia ...
Ronald Zambrano (5497406), Younghye Moon (200726), Shu Wu (492135), Shihua Luo (5497415), Yong Bao (296790), Luqing Wang (5257895), Merline Benny (5497403), Justin Percival (5497412), Ling Qin (68169), Fredrick Dapaah-Siakwan (5497409), Matthew R. Duncan (5497421), Keyur Donda (5497400), Karen Young (833929), Ruben Vaidya (5497418)   +13 more
core   +1 more source

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data

Рациональная фармакотерапия в кардиологии, 2020
This narrative review describes and appraises some relatively new studies investigating the efficacy and safety profile of soluble guanylate cyclase stimulator riociguat in patients suffering from pulmonary arterial hypertension (PAH) and chronic ...
M. A. Simakova, O. M. Moiseeva
doaj   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Riociguat: Mode of action and clinical development in pulmonary hypertension [PDF]

, 2016
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary vasculature, leading to elevated pulmonary artery pressure and
Langleben, D, Ghofrani, HA, Humbert, M, Wilkins, MR, Schermuly, R, Stasch, JP, Klinger, JR   +6 more
core   +1 more source

Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real‐World US Claims Data Analysis

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT This study quantified the recent real‐world burden of pulmonary arterial hypertension (PAH) using US real‐world data. Adults (18+) with treated PAH were identified from the MarketScan Commercial/Medicare Databases using a claims‐based algorithm requiring pulmonary hypertension diagnosis, PAH‐specific treatment, and right heart catheterization ...
Ashwin Ravichandran, Amélie Beaudet, David Lopez, Carolyn R. Lew, Helen Varker, Michelle Jerry, Akshay Muralidhar   +6 more
wiley   +1 more source